Skip to main content
OPTUS Pharmaceutical Co., Ltd. logo

OPTUS Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 131030 ISIN · KR7131030009 KO Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2022-09-07 Transaction in Own Shar…
Country KR South Korea
Listing KO 131030

About OPTUS Pharmaceutical Co., Ltd.

http://optuspharm.com/us/main/index.php

OPTUS Pharmaceutical Co., Ltd. is a specialized pharmaceutical company focused on the research, development, manufacturing, and commercialization of ophthalmic products. The company's primary expertise lies in producing sterile, preservative-free, single-dose (unit-dose) formulations. Its therapeutic portfolio addresses conditions such as dry eye syndrome, keratoconjunctival epithelial disease, bacterial conjunctivitis, and glaucoma. In addition to prescription and over-the-counter pharmaceuticals, the company is expanding into a total eye care model through its OUE& brand, which encompasses nutritional supplements (OUEFIT) and cosmeceuticals (OUELAB). The company operates EU-GMP certified manufacturing facilities and distributes its products globally.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Optus Pharm, specifically detailing a 'Decision to Acquire Treasury Shares' (자기주식 취득 결정). This filing outlines the company's plan to buy back its own shares from the market for the purpose of stock price stabilization and shareholder value enhancement. According to the provided definitions, a report of a company buying back its own shares is classified as 'Transaction in Own Shares' (POS).
2022-09-07 Korean
[기재정정]주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) from Optus Pharm regarding a decision to acquire treasury shares (자기주식 취득 결정). It details the purpose, quantity, and method of the share buyback, which falls under the category of a company buying back its own shares. According to the provided definitions, this is classified as 'Transaction in Own Shares' (POS).
2022-09-07 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Optus Pharmaceutical Co., Ltd., covering the period from January 1, 2022, to June 30, 2022. It contains detailed financial information, business operations, and management disclosures, which is characteristic of an interim/quarterly report. It is not an announcement of a report, but the report itself. H1 2022
2022-08-16 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회결과' (Extraordinary General Meeting Results) and provides the outcome of specific agenda items (approval of articles of incorporation changes) from a shareholder meeting held on 2022-06-03. This falls under the category of Declaration of Voting Results.
2022-06-03 Korean
본점소재지변경
Regulatory Filings Classification · 100% confidence The document is a short regulatory announcement regarding a change in the company's registered office address (본점소재지변경). It does not fit into specific categories like financial reports, dividends, or share transactions. As it is a general regulatory disclosure filed with the KRX, it falls under the fallback category for regulatory announcements.
2022-06-03 Korean
상호변경안내
Regulatory Filings Classification · 100% confidence The document is a short announcement regarding a change of company name (from DHP KOREA to OPTUS Pharmaceutical). It does not fit into specific financial reporting categories like 10-K, IR, or ER. Since it is a regulatory announcement regarding corporate identity changes that does not fall into the other specific categories, it is classified as a general regulatory filing.
2022-06-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.